

Overview of diagnosis of diabetes mellitus type 2 in primary care

Ohood Saeed AlGhamdi, Mona Saeed AlZahrani, Nehal Saad AlThagafi

Abstract:

The present review provides a discussion of recommended approaches to screening, diagnosis, and treatment in patients with T2DM, as well as in those at risk for the disease. Detailed search and review of the literature was conducted using electronic databases, MEDLINE, EMBASE, and SCISEARCH; up to December, 2017, for studies reporting data on diagnosis of diabetes mellitus type 2 in primary care. Primary care clinicians face several difficulties in the inherently complicated management of diabetes. They struggle to meet evolving treatment targets within restricted time and sources, and express frustrations with resulting compromises in care. A range of environmental elements including poor dietary quality, insufficient physical activity, and sedentary lifestyles have assembled in the past 2 decades to produce an unprecedented epidemic of childhood obesity and its most serious complication, type 2 diabetes mellitus. As a result of this epidemic, we face the prospect of coronary heart disease coming to be a disease of young adulthood. The primary care clinician should play an active role in both the primary prevention of obesity and the timely diagnosis and treatment of type 2 diabetes mellitus in kids especially. Effective management of T2DM requires an interaction between health providers delivering treatments and well-informed patients implementing self-management approaches.

Introduction:

Historically, diabetes mellitus has been classified as either juvenile-onset (currently referred to as type 1) or adult-onset (type 2) due to distinctive distinctions in the common age of presentation of these 2 problems. With the increasing occurrence of type 2 diabetes mellitus in youngsters, these terms have become inaccurate. Recent estimates suggest that type 2 diabetes mellitus could currently make up as lots of as half of all brand-new cases of diabetes in certain pediatric populations. This apparent epidemic, attributable greatly to the increased rates of obesity in children, carries huge long-term public health implications. This article will take into consideration these implications, analyze the pathophysiology of type 2 diabetes mellitus in kids, and evaluation prevention and treatment strategies.

Cardiovascular disease is the predominant reason for morbidity and death in patients with T2DM. Moreover, patients with T2DM, as well as those at risk for T2DM, have a high frequency of comorbidities, consisting of obesity, dyslipidemia, and hypertension, which likewise enhances their danger for cardiovascular disease and other T2DM-related complications [1].

In spite of the high prevalence of both prediabetes and undiagnosed diabetes, the worth of universal testing for T2DM stays questionable. Practice standards have been published that could assist in identification of at-risk individuals and maximize screening treatments [1], [2].

Evidence-based standards are available that give reliable therapy methods for patients with prediabetes and T2DM [2], [3]. Accomplishing advised professional goals substantially minimizes the threat of morbidity and death [4]. Nonetheless, numerous patients fail to maintain glycemic

control [5], which may lead to progression of illness in addition to serious microvascular and macrovascular difficulties.

The present review provides a discussion of recommended approaches to screening, diagnosis, and treatment in patients with T2DM, as well as in those at risk for the disease.

Methodology:

Detailed search and review of the literature was conducted using electronic databases, MEDLINE, EMBASE, and SCISEARCH; up to December, 2017, for studies reporting data on diagnosis of diabetes mellitus type 2 in primary care. With keywords as following; “diabetes”, “type2 diabetes mellitus”, “primary care”, “family medicine”. Restriction to studies published in English and with human subjects was applied in our search strategies.

Discussion:

- **Diagnosis**

Identifying At-Risk Patients and Optimizing Screening

Patients in jeopardy for T2DM consist of those with cardiovascular disease, dyslipidemia, excessive weight, a sedentary lifestyle, or a family history of diabetic issues mellitus, along with

participants of details racial and ethnic minority teams (Figure 1) [6]. Regardless of the high occurrence of prediabetes and undiagnosed T2DM, the value of office-based screening for T2DM in asymptomatic patients remains uncertain. While readily available data usually do not sustain this practice, the outcomes of some studies recommend that testing patients with multiple threat factors for T2DM, particularly during routine office visits, may be worthwhile [7].

A number of professional organizations have released guidelines that identify details teams that should go through T2DM testing (Figure 2) [6], [8]. These suggestions are related to a few of the recognized danger aspects for the development of T2DM. Primary care physicians may locate these recommendations a valuable starting point where to additionally sharpen their very own testing criteria, based upon the patient demographics and specific danger factors that they see most frequently in their private methods.

- 
- ☐ Family history of diabetes
 - ☐ Cardiovascular disease
 - ☐ Overweight or obese state
 - ☐ Sedentary lifestyle
 - ☐ Latino/Hispanic, non-Hispanic black, Asian American, Native American, or Pacific Islander ethnicity
 - ☐ Previously identified impaired glucose tolerance or impaired fasting glucose
 - ☐ Hypertension
 - ☐ Increased levels of triglycerides, low concentrations of high-density lipoprotein cholesterol, or both
 - ☐ History of gestational diabetes
 - ☐ History of delivery of an infant with a birth weight >9 pounds
 - ☐ Polycystic ovary syndrome
 - ☐ Psychiatric illness

Figure 1. Risk factors for prediabetes and diabetes mellitus and potential screening criteria for primary care physicians[6].

Our understanding of the risk factors connected with the advancement of T2DM continues to expand and improve. As Figure 1 shows, danger variables might be associated with personal or family history (eg, family history of diabetes mellitus, previously recognized sugar intolerance, personal history of gestational diabetes mellitus), comorbidities (eg, hypertension, dyslipidemia, polycystic ovary syndrome, psychiatric disease), and race or ethnic background [6]. An awareness of these potential warnings and medical ideas such as acanthosis nigricans could aid the primary care provider determine patients looking for testing who might or else be ignored.

Guideline	Population to Be Screened
US Preventive Service Task Force ⁹	Adults with blood pressure >135/80 mm Hg
American Academy of Family Physicians ¹⁰	Adults with both hypertension and hyperlipidemia
Canadian Task Force for Preventive Health Care ¹¹	Adults with hypertension, hyperlipidemia, or both
American College of Obstetricians and Gynecologists ¹²	Women aged ≥45 years
American Diabetes Association ¹³	Adults aged ≥45 years or <45 years if body mass index ≥25 with additional risk factors
American Association of Clinical Endocrinologists ⁷	Adults at increased risk for diabetes beginning at age 30 years

Figure 2. Patient populations recommended for diabetes screening[8].

Taking a Multidisciplinary Approach

Given the demands of a busy primary care practice, it could be difficult to comply with clinical practice guidelines. Lack of time during medical professional office brows through and absence of information regarding gaps in patient care (eg, unacceptable control of blood pressure and cholesterol levels) are major obstacles to standard adherence [10]. To deal with these obstacles,

the existing standards suggest an office-wide multidisciplinary approach. In this structure, the health care doctor serves as the group leader, who is responsible for working with the identification and screening of patients in jeopardy for T2DM. Throughout patient intake, nurses or other workplace staff can be assigned to inquire about and record danger elements for usual diseases, including T2DM. Innovation could additionally aid in determining patients at risk. Digital medical records can assist in within-office care control by offering digital messaging and easy access to information during patient office visits [11]. Along with screening tips, health and wellness information technology could be utilized to develop a computer registry of the patient populace with T2DM with care prompts and choice sustains. The computer registry could additionally provide accessibility to released evidence and patient instructional products [12].

Screening: Where Does HbA_{1c} Testing Fit?

For years, the diagnosis of T2DM has been based upon plasma glucose criteria: either a fasting plasma glucose (FPG) level of 126 mg/dL or higher, a 2-hour postprandial glucose (PPG) degree of 200 mg/dL or higher after ingestion of 75 g of oral glucose, or an arbitrary plasma glucose level of greater than 200 mg/dL with signs and symptoms of diabetes mellitus such as polyuria, polydipsia, or weight loss. The use of other steps-- such as HbA_{1c} degrees, which show long-term glycemic exposure- has been the subject of recurring argument. In 2008, an International Expert Committee with members standing for the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the International Diabetes Foundation convened and advised that the medical diagnosis of T2DM be made if the HbA_{1c} degree is 6.5% or greater; the ADA verified this choice [9], [13]. One limitation of gauging HbA_{1c} degrees is that, since it is a hemoglobin-based examination, anemia or hemoglobinopathies might interfere with the validity of the results. Several physicians recognize

that dimension of HbA1c levels is a powerful device, yet they still take into consideration measurement of FPG and PPG degrees to be the requirement of screening. If HbA1c testing is not feasible, medical diagnosis needs to be based on previously recommended diagnostic approaches (eg, dimension of FPG levels or 2-hour PPG levels, with verification by repeat screening on a different day) [13].

As a practical issue, if a patient's FPG and HbA1c levels are both raised, even though the guidelines recommend that the medical diagnosis not be made up until the test outcomes are confirmed, many doctors will assume T2DM is present and base their suggestions to the patient on the basis of that presumption-- without necessarily offering the patient that medical diagnosis till they have had an opportunity to confirm it with repeat screening. Arriving at a correct, legitimate diagnosis is specifically essential for patients with T2DM, due to the fact that any type of mistake could cause misinformation in medical records and difficulty with healthcare insurance once the medical diagnosis of T2DM refers record.

Set Goals for Glycemic Control in Patients With Newly Diagnosed Disease

In establishing HbA1c goals for patients with T2DM, physicians could rely on clinical standards published by several specialist associations. A recent joint position statement by the ADA, the American College of Cardiology Foundation, and the American Heart Association reviewed a number of clinical trials (including ACCORD and ADVANCE) and concluded that reducing HbA1c degrees to less than 7% can reduce the microvascular and neuropathic difficulties of T2DM [14]. In addition, long-lasting macrovascular advantages might be achieved in patients with freshly diagnosed disease by their maintaining HbA1c levels at less than 7%, and incremental advantages may be accomplished by more decrease of HbA1c levels in choose patients, such as those with long life span and no medically substantial cardiovascular disease.

The American Association of Clinical Endocrinologists (AACE) recommends preserving a more rigid glycemic target of HbA1c levels at 6.5% or reduced [15].

Numerous patients have to return regularly for office visits initially of their therapy. When the management process is established, a good rule of thumb for return visits is every 3 months. Some patients think that such regular office visits are unneeded, yet it must be comprehended that the condition could change quickly, also within that brief quantity of time. As such, it is very important to keep an eye on patients very closely and readjust their therapy as necessary.

- **Prevention and Treatment**

Two central principles concerning the management of type 2 diabetes mellitus need to be highlighted. First, frank diabetes stands for a late metabolic decompensation of a chronic condition process. The increased risk of cardiovascular complications starts early in this illness process before formal diagnostic criteria for diabetes have been reached. Since no clear distinction exists in between prevention and therapy, the relevance of a healthy diet plan and a literally active way of life need to be highlighted for all overweight children. Second, since type 2 diabetes mellitus is caused by relative insulin shortage in the setting of insulin resistance, ideal therapy needs measures to decrease insulin resistance.

Weight Loss. The cornerstone of therapy for kind 2 diabetes mellitus is weight loss. Demonstrable enhancement in insulin sensitivity accompanies modest weight-loss. Substantial weight-loss could produce total normalization of blood glucose degrees and possibly irreversible resolution of diabetes [16], [17]. Sadly, conventional therapy for obesity usually has poor long-term success [18] While a discussion of current treatment alternatives for pediatric obesity is past the range of this review, a multidisciplinary approach, involving

dietary adjustment, raised physical activity, lowered sedentary time, and behavior modification, uses the very best wish for an effective outcome [19], [20].

Dietary Composition. Several dietary factors could affect condition advancement and development independent of body weight. Typically, reduced- fat and/or high-carbohydrate diets have been recommended for the prevention and therapy of type 2 diabetic issues mellitus. Recently, some investigators have argued that such diets promote insulin resistance and, because of this, have advocated greater fat and reduced carbohydrate consumption [21]. Although the total quantity of dietary fat shows up to have little result on condition threat, the kind of fat might be essential. Partially hydrogenated fat (trans-fat), which is typically located in business food products, enhances danger, whereas polyunsaturated fat from veggie and marine sources lowers danger [22]. An additional potentially essential factor might be the kind of nutritional carbohydrate. Habitual usage of low glycemic index foods (ie, foods that create a fairly tiny postprandial boost in blood glucose) might decrease the threat of type 2 diabetes mellitus [23] and improve metabolic control once the condition has created [24]. A low-glycemic-index diet might likewise promote weight-loss, though this opportunity has not been taken a look at in lasting professional tests [25].

Physical Activity. Independent of its effects on body weight and make-up, physical activity boosts insulin sensitivity and glucose tolerance. Also moderate levels of exercise, such as everyday strolling, have been revealed to decrease risk for type 2 diabetes mellitus in adults. On the other hand, sedentary activities, such as television viewing, have been revealed to boost danger for obesity [25], [26].

Pharmacologic Agents That Increase Insulin Sensitivity. An overall of 3 classes of medicines for the treatment of diabetes act by improving insulin sensitivity or lowering insulin demand,

though none have been approved for use in children by the Food and Drug Administration. The biguanides (eg, metformin) decrease hepatic glucose production and improve fasting hyperglycemia. α -Glucosidase preventions (eg, acarbose) delay the digestion and absorption of starchy food, and improve postprandial hyperglycemia. The thiazolidinediones (eg, rosiglitazone) increase peripheral insulin sensitivity. Metformin has been used safely in youngsters and does not trigger weight gain [27].

Pharmacologic Agents That Increase Insulin Levels. The 3 classes of medicines in this group are sulfonylureas, meglitinides (eg, repaglinide), which stimulate endogenous insulin secretion, and insulin itself. In our opinion, these representatives need to not be taken into consideration first-line therapy for type 2 diabetes mellitus because they do not deal with insulin resistance and due to the fact that they have vital unfavorable impacts (weight gain and hypoglycemia). Nonetheless, insulin could end up being essential if other procedures fail to establish appropriate glycemic control or in the event of an acute metabolic decompensation.

Conclusion:

Primary care clinicians face several difficulties in the inherently complicated management of diabetes. They struggle to meet evolving treatment targets within restricted time and sources, and express frustrations with resulting compromises in care. A range of environmental elements including poor dietary quality, insufficient physical activity, and sedentary lifestyles have assembled in the past 2 decades to produce an unprecedented epidemic of childhood obesity and its most serious complication, type 2 diabetes mellitus. As a result of this epidemic, we face the prospect of coronary heart disease coming to be a disease of young adulthood. The primary care clinician should play an active role in both the primary prevention of obesity and the timely

diagnosis and treatment of type 2 diabetes mellitus in kids especially. Effective management of T2DM requires an interaction between health providers delivering treatments and well-informed patients implementing self-management approaches.

Reference:

1. American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(suppl 1):S11-S61.
2. Handelsman Y, Mechanick JJ, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(suppl 2): 1-53.
3. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933-946.
4. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765-1772.
5. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81-86.
6. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1): 1-68.
7. O'Connor PJ, Rush WA, Cherney LM, Pronk NP. Screening for diabetes mellitus in high-risk patients: cost, yield, and acceptability. Eff Clin Pract. 2001;4 (6):271-277.

8. US Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: US Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2008;148(11):846-854.
9. American Diabetes Association. Standards of medical care in diabetes—2010. *Diabetes Care.* 2010;33(suppl 1):S11-S61.
10. Weber V, Bloom F, Pierdon S, Wood C. Employing the electronic health record to improve diabetes care: a multifaceted intervention in an integrated delivery system. *J Gen Intern Med.* 2008;23(4):379-382.
11. O'Malley AS, Grossman JM, Cohen GR, Kemper NM, Pham HH. Are electronic medical records helpful for care coordination? experiences of physician practices. *J Gen Intern Med.* 2010;25(3):177-185.
12. Hunt JS, Siemieniczuk J, Gillanders W, et al. The impact of a physician-directed health information technology system on diabetes outcomes in primary care: a preand post-implementation study. *Inform Prim Care.* 2009;17(3):165-174.
13. The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care.* 2009;32(7):1327-1334.
14. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials—a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. *J Am Coll Cardiol.* 2009;53(3):298-304.
15. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract.* 2009;15(6):540-559.
16. Methods for voluntary weight loss and control: NIH Technology Assessment Conference Panel. *Ann Intern Med.* 1993;119:764-770.
17. Bar-Or O, Foreyt J, Bouchard C, et al. Physical activity, genetic, and nutritional considerations in childhood weight management. *Med Sci Sports Exerc.* 1998;30:2-10.
18. Trent ME, Ludwig DS. Adolescent obesity, a need for greater awareness and improved treatment. *Curr Opin Pediatr.* 1999;11:297-302.
19. Reaven GM. Do high carbohydrate diets prevent the development or attenuate the manifestations (or both) of syndrome X? a viewpoint strongly against. *Curr Opin Lipidol.* 1997;8:23-27.
20. Salmeron J, Hu FB, Manson JE, et al. Dietary fat intake and risk of type 2 diabetes in women. *Am J Clin Nutr.* 2001;73:1019-1026.
21. Salmeron J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willett WC. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. *JAMA.* 1997;277:472-477.
22. Miller JC. Importance of glycemic index in diabetes. *Am J Clin Nutr.* 1994;59(suppl 3):747S-752S.
23. Ludwig DS. Dietary glycemic index and obesity.
24. *J Nutr.* 2000;130:280S-283S.

25. Gortmaker SL, Must A, Sobol AM, Peterson K, Colditz GA, Dietz WH. Television viewing as a cause of increasing obesity among children in the United States, 1986-1990. Arch Pediatr Adolesc Med. 1996; 150:356-362.
26. Epstein LH, Paluch RA, Gordy CC, Dorn J. Decreasing sedentary behaviors in treating pediatric obesity. Arch Pediatr Adolesc Med. 2000;154:220-226.
27. Freemark MF, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001; 107:E55.

IJSER